Enovis Corp traded at $20.04 this Wednesday July 1st, decreasing $0.66 or 3.19 percent since the previous trading session. Looking back, over the last four weeks, Enovis lost 8.66 percent. Over the last 12 months, its price fell by 40.11 percent. Looking ahead, we forecast Enovis Corp to be priced at 22.24 by the end of this quarter and at 20.88 in one year, according to Trading Economics global macro models projections and analysts expectations.
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity tools. It also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.